Evidence map›Paper›PMID 39789407›Full record

ArticleCell biology and toxicology2025

ANXA10 sensitizes microsatellite instability-high colorectal cancer to anti-PD-1 immunotherapy via assembly of HLA-DR dimers by regulating CD74.

Yiting Sun, Bowen Yang, Ti Wen, Xiaoyu Guo, Danni Li, Ruichuan Shi, Fuqiang Zhang, Dongni Wang, Ce Li, Xiujuan Qu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell biology and toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. CD74Journal of gastrointestinal cancer · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yiting Sun *Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, Liaoning, China.
Bowen Yang *Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, Liaoning, China.
Ti WenDepartment of Medical Oncology, the First Hospital of China Medical University, Shenyang, Liaoning, China.
Xiaoyu GuoDepartment of Medical Oncology, the First Hospital of China Medical University, Shenyang, Liaoning, China.
Danni LiDepartment of Medical Oncology, the First Hospital of China Medical University, Shenyang, Liaoning, China.
Ruichuan ShiDepartment of Medical Oncology, the First Hospital of China Medical University, Shenyang, Liaoning, China.
Fuqiang ZhangDepartment of Anus and Intestine Surgery, the First Hospital of China Medical University, Shenyang, Liaoning, China.
Dongni WangDepartment of Medical Oncology, the First Hospital of China Medical University, Shenyang, Liaoning, China.
Ce LiDepartment of Medical Oncology, the First Hospital of China Medical University, Shenyang, Liaoning, China. cmulice@126.com.
Xiujuan QuDepartment of Medical Oncology, the First Hospital of China Medical University, Shenyang, Liaoning, China. xjqu@cmu.edu.cn.ORCID 0009-0005-9366-2314

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicrosatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) patients are the dominant population in immune checkpoint blockade treatments, while more than half of them could not benefit from single-agent immunotherapy. We tried to identify the biomarker of MSI-H CRC and explore its role and mechanism in anti-PD-1 treatments. Tumor-specific MHC-II was linked to a better response to anti-PD-1 in MSI-H CRC and CD74 promoted assembly and transport of HLA-DR dimers.

methodsThe characteristic gene was screened by data analysis of single-cell and bulk transcriptome sequencing from public datasets. MSI-H CRC cells co-cultured with peripheral blood mononuclear cells and syngeneic model in C57BL/6 mice were performed to detect the sensitivity to anti-PD-1 treatments respectively.

resultsANXA10 was identified as a characteristic gene of MSI-H CRC and its expression was obviously greater in MSI-H than MSS CRC. ANXA10 significantly sensitized MSI-H CRC to anti-PD-1 treatments in vitro and in vivo. Specifically, ANXA10 promoted HLA-DR dimers in and on the surface of MSI-H CRC by increasing CD74 expression. Besides, this work demonstrated that ANXA10 contributed to better clinical benefits with anti-PD-1 therapy in MSI-H CRC patients.

conclusionsOur results provided a novel molecular marker ANXA10 to identify benefit population of MSI-H CRC for improving efficacy of anti-PD-1 and contributed to selection of treatment strategies.

Indexed as

Colorectal NeoplasmsHLA-DR AntigensImmune Checkpoint InhibitorsImmunotherapyMice, Inbred C57BLMicrosatellite InstabilityAnimalsAntigens, Differentiation, B-LymphocyteCell Line, TumorFemaleHistocompatibility Antigens Class IIHumansMaleMiceProgrammed Cell Death 1 ReceptorAntigens, Differentiation, B-LymphocyteHistocompatibility Antigens Class IIHLA-DR AntigensImmune Checkpoint Inhibitorsinvariant chainProgrammed Cell Death 1 ReceptorANXA10Microsatellite instability-high colorectal cancerSensitivity to anti-PD-1 therapyTumor-specific MHC-II

Identifiers

PMID39789407
PMCPMC11717857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.